Navitoclax (ABT-263)

For research use only. Not for use in humans.

Catalog No.S1001

158 publications

Navitoclax (ABT-263) Chemical Structure

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 400 In stock
USD 120 In stock
USD 200 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Navitoclax (ABT-263) has been cited by 158 publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Targets
Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki)
In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell M362[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MomzTWM2OD1yLkCwOlY6KM7:TR?= MYDTRW5ITVJ?
MV-4-11 M2HzeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTBwMEG1PFYh|ryP M4PPc3NCVkeHUh?=
NKM-1 NXfxbpl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYf2b3p[UUN3ME2wMlAyPjl7IN88US=> MX\TRW5ITVJ?
ML-2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7YT|BQUUN3ME2wMlAyQTh|IN88US=> NVzyfFB1W0GQR1XS
BV-173 NIrnV|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlf6TWM2OD1yLkCyN|E1KM7:TR?= NXrK[HFoW0GQR1XS
RS4-11 M1PRSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\i[GlEPTB;MD6wNlU5PyEQvF2= NGTzeZdUSU6JRWK=
HL-60 NXn5OZVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwMEK5NFgh|ryP M{DTfXNCVkeHUh?=
KY821 NYDGUY1qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTBwMEK5O|Uh|ryP NUjyPJhKW0GQR1XS
ECC10 NFzhVWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mon0TWM2OD1yLkCzO|kzKM7:TR?= M{HCNXNCVkeHUh?=
NCI-H720 NYLFU5hHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDyR2xbUUN3ME2wMlA1ODFzIN88US=> M4fV[HNCVkeHUh?=
QIMR-WIL NFLFSmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TkPGlEPTB;MD6wOFI5PyEQvF2= NYr1bZk6W0GQR1XS
KG-1 MlflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF6yd|FKSzVyPUCuNFQ1QDZizszN Mnv6V2FPT0WU
TGW NEfqXHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjHb2JKSzVyPUCuNFQ3OzNizszN NXTyWmtLW0GQR1XS
ATN-1 MkPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DoTGlEPTB;MD6wOFc{OyEQvF2= Ml71V2FPT0WU
RH-18 M1HwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PGc2lEPTB;MD6wOlA1QCEQvF2= MVXTRW5ITVJ?
EW-18 M3nRRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjwWJd7UUN3ME2wMlA3QDRzIN88US=> MomxV2FPT0WU
NB17 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\EV2pZUUN3ME2wMlA4OTJ2IN88US=> MYLTRW5ITVJ?
SK-NEP-1 NYjXVph[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrxTHhKSzVyPUCuNFczOTNizszN MX7TRW5ITVJ?
P12-ICHIKAWA MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEC1cVFKSzVyPUCuNFc4PzhizszN MUXTRW5ITVJ?
KARPAS-45 M{jQSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljhTWM2OD1yLkC3PFE2KM7:TR?= MWHTRW5ITVJ?
EW-3 M1rjRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXzdWdKSzVyPUCuNFgxPTNizszN MXzTRW5ITVJ?
NB13 NVvwbI1PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPrbXdKSzVyPUCuNFgzODNizszN NHjndY5USU6JRWK=
NCI-H209 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnkb2ZKSzVyPUCuNFg4ODRizszN MknqV2FPT0WU
NCI-H1092 NYPs[29RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PUR2lEPTB;MD6xNFI4PSEQvF2= M3PXenNCVkeHUh?=
NH-12 MnP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwMUC3OFQh|ryP M3P3RnNCVkeHUh?=
697 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\0eGlEPTB;MD6xNFg{QSEQvF2= NFTWeHlUSU6JRWK=
KE-37 M4fKNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXLclRKSzVyPUCuNVE{PyEQvF2= NVHHTGtMW0GQR1XS
MOLT-4 NVrRVWVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwMUWxOlkh|ryP NUP2[HdbW0GQR1XS
CHP-134 NV7CcIlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwMU[zNFYh|ryP MWjTRW5ITVJ?
D-283MED NEOwdYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrhc2pNUUN3ME2wMlE4Pjh4IN88US=> NXvBUYI3W0GQR1XS
LU-135 MkflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDmVYlKSzVyPUCuNVg2PTJizszN MWXTRW5ITVJ?
LU-134-A NHnVUY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7tfW1KSzVyPUCuNVg3PzFizszN NYnSWJJEW0GQR1XS
EM-2 NF[3TZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jEb2lEPTB;MD6xPVkyQCEQvF2= MX7TRW5ITVJ?
LU-139 NXjkUWtoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGO3Xo5KSzVyPUCuNlA1QThizszN Ml\qV2FPT0WU
ALL-PO MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjVTWM2OD1yLkKxPVg5KM7:TR?= M3TydnNCVkeHUh?=
NB12 Mn62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzsW4M4UUN3ME2wMlI{OTF3IN88US=> MYHTRW5ITVJ?
KP-N-YN MoTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fOTGlEPTB;MD6yN|U4OyEQvF2= M2TLPHNCVkeHUh?=
BEN NFHI[GdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrsfW5KSzVyPUCuNlM6PjhizszN NGHBdI5USU6JRWK=
HCC1569 M2TjPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHMUY5KSzVyPUCuNlUyODZizszN NXHLZ3lvW0GQR1XS
HuO9 NEDFTJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfFfmZKSzVyPUCuNlY4OTVizszN M1vRNXNCVkeHUh?=
WM-115 NV\FVHhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojqTWM2OD1yLkK3O|M5KM7:TR?= M{\TTXNCVkeHUh?=
CCRF-CEM Ml74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTBwM{O1Nlkh|ryP MoG0V2FPT0WU
IST-SL1 NEXrW4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nCemlEPTB;MD6zOVM1OyEQvF2= NWLic|loW0GQR1XS
BE-13 NXjwNVJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17VU2lEPTB;MD6zOlQ2QSEQvF2= MV3TRW5ITVJ?
COR-L88 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDHTWM2OD1yLkO2OVQh|ryP MYHTRW5ITVJ?
DOHH-2 NYHjVZBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoixTWM2OD1yLkSxNFI{KM7:TR?= MkftV2FPT0WU
A704 M{e3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\Pc3dKSzVyPUCuOFI3PyEQvF2= M2rRPXNCVkeHUh?=
KNS-81-FD NUnLb4JqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTBwNESwNVch|ryP M1;YRnNCVkeHUh?=
RPMI-8226 NXWwNlJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTBwNEW2OVIh|ryP Mn74V2FPT0WU
TGBC24TKB NYW1N5kyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXvUoZKSzVyPUCuOFU4PzhizszN M{LwV3NCVkeHUh?=
NCI-H1304 NX72WmZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHsTWM2OD1yLkS2NVU4KM7:TR?= M2e3S3NCVkeHUh?=
MOLT-13 NUHpR2J[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PKXWlEPTB;MD60OlYyOyEQvF2= M37LR3NCVkeHUh?=
EW-22 M2nJPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwNE[2O|Eh|ryP NWrUWIp[W0GQR1XS
MS-1 NGK4[o5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXFWXZKSzVyPUCuOFY6OzNizszN NWr0SVg3W0GQR1XS
RMG-I M2HSfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrtUZppUUN3ME2wMlQ6PDZ2IN88US=> M{nyO3NCVkeHUh?=
NTERA-S-cl-D1 NWnuVINkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjPXYVRUUN3ME2wMlUxODF7IN88US=> NFTYWXZUSU6JRWK=
NCI-H1048 MmDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{GweGlEPTB;MD61NFk2OyEQvF2= NU[xfoZ5W0GQR1XS
SW1417 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGm2bYlKSzVyPUCuOVU1OzhizszN NFz6OpRUSU6JRWK=
DB NFjXd2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4C4RWlEPTB;MD61O|A5KM7:TR?= M3WzVnNCVkeHUh?=
MEG-01 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwNUizNkDPxE1? NEHYc|JUSU6JRWK=
EW-13 M4e2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTBwNUizOFEh|ryP MkOwV2FPT0WU
LAMA-84 NGPucodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\nTWM2OD1yLkW5NlA4KM7:TR?= NFv0[5ZUSU6JRWK=
J-RT3-T3-5 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjXPXBKSzVyPUCuOlA5ODhizszN M1XXbHNCVkeHUh?=
MOLT-16 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3naRmlEPTB;MD62OVI3PCEQvF2= NI\zbXVUSU6JRWK=
DU-4475 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmn4TWM2OD1yLk[1OFI4KM7:TR?= NX[xNll[W0GQR1XS
HAL-01 MmKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\1OmlEPTB;MD63NlU1QSEQvF2= NHPiOWlUSU6JRWK=
RD MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwN{W4PVkh|ryP MlG5V2FPT0WU
OAW-28 NUPTe5pQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwN{izO{DPxE1? NYj6VWxUW0GQR1XS
HCC38 MoruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXMTWM2OD1yLkiwNVkh|ryP M1jufHNCVkeHUh?=
NMC-G1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PnZmlEPTB;MD64NVEzOSEQvF2= MoHhV2FPT0WU
EW-16 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUm1fY51UUN3ME2wMlgyOzJ6IN88US=> MlnGV2FPT0WU
DU-145 MkTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXwdJZKSzVyPUCuPFk6OjNizszN MYfTRW5ITVJ?
HPAF-II Mn25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTBwOUK2Nlgh|ryP MlXVV2FPT0WU
A427 M{f3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTBwOUOwNlIh|ryP MWLTRW5ITVJ?
PA-1 MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXkTIdmUUN3ME2wMlk2PjR{IN88US=> M4fIVnNCVkeHUh?=
OAW-42 NGr6[XpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTBwOU[xOFYh|ryP NXnReJE4W0GQR1XS
L-428 NFr3eXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTFwMEGyOUDPxE1? NEHaR2NUSU6JRWK=
COLO-824 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFf4VFdKSzVyPUGuNFE4ODhizszN MVPTRW5ITVJ?
P30-OHK MkO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHWfZl3UUN3ME2xMlA1Pjh6IN88US=> MlrJV2FPT0WU
NCI-H2170 NH3HS4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFn2PXNKSzVyPUGuNFYzOyEQvF2= Ml23V2FPT0WU
HCC2998 MljNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\oXGpKSzVyPUGuNFcyOzVizszN Ml3HV2FPT0WU
NB14 NUHPT4FLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHj2UVNKSzVyPUGuNVM4PDhizszN M1;6WnNCVkeHUh?=
TGBC1TKB M1P5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XhNWlEPTB;MT6xOFE2OiEQvF2= M1PlRXNCVkeHUh?=
KP-N-YS NY\uR2RtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInwPVFKSzVyPUGuNVYzOzZizszN NVThV2QxW0GQR1XS
CAL-120 M3XqdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPWZoNJUUN3ME2xMlE3PDJ7IN88US=> MnXkV2FPT0WU
SBC-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknMTWM2OD1zLkG5NFU{KM7:TR?= MX3TRW5ITVJ?
C32 NUfue452T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnn[YtKSzVyPUGuNVkxQDhizszN NIXvTmhUSU6JRWK=
HCC2157 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LwV2lEPTB;MT6xPVQ6PCEQvF2= Ml75V2FPT0WU
COLO-792 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4q0TWlEPTB;MT6yNFA4OSEQvF2= NHrTTVZUSU6JRWK=
ES7 MmfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHnTWM2OD1zLkK3PVUyKM7:TR?= M4LyXHNCVkeHUh?=
HEL M4jSXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmL4TWM2OD1zLkOxNFI6KM7:TR?= M4jvT3NCVkeHUh?=
ES4 Mor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTFwM{S5PVgh|ryP M{PTeHNCVkeHUh?=
NCI-SNU-1 NIW5TYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTFwM{[1OVUh|ryP M2q4VHNCVkeHUh?=
MDA-MB-415 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HTcWlEPTB;MT6zPFg2KM7:TR?= M1LzN3NCVkeHUh?=
NCI-H2342 NWHXV3dGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTFwNECyOlkh|ryP M3zBVXNCVkeHUh?=
NB69 MnmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYG0b4NYUUN3ME2xMlQ3OjdzIN88US=> M{jVcHNCVkeHUh?=
D-247MG M4ntV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIm1fndKSzVyPUGuOVEyOjJizszN NW\vWoZpW0GQR1XS
SCC-4 NUWzSXdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDHTWM2OD1zLkW5PFg4KM7:TR?= NIXIN4ZUSU6JRWK=
HuH-7 NYjtOFNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTFwNkeyPVMh|ryP NFTt[4VUSU6JRWK=
A388 NVfVbHl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfXOIhKSzVyPUGuOlg4OjRizszN MYLTRW5ITVJ?
Calu-3 NX;Oe3B{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jJdGlEPTB;MT63NFY6PyEQvF2= NUGzTIM5W0GQR1XS
NCI-H1648 NELWW|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELUVYtKSzVyPUGuO|E1OThizszN NVzNS4ZTW0GQR1XS
NCI-H2052 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHK5V2FKSzVyPUGuO|IzODFizszN M4DiZ3NCVkeHUh?=
Ramos-2G6-4C10 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LDWmlEPTB;MT63N|Y2PiEQvF2= M2HpPHNCVkeHUh?=
DEL MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3H5emlEPTB;MT63OFY6OiEQvF2= NHmwdmlUSU6JRWK=
SNU-423 NID3clBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTFwN{ixOVch|ryP MmLnV2FPT0WU
COR-L23 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\nTWM2OD1zLke5PFc1KM7:TR?= MnW0V2FPT0WU
OMC-1 MoXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTFwOE[wNVYh|ryP NXnR[2hSW0GQR1XS
EW-11 M{\wRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjafXpKSzVyPUGuPVU3PTdizszN M1rkNHNCVkeHUh?=
HSC-3 NHzKbGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFT6T5BKSzVyPUGuPVY{PjVizszN NHXwVI1USU6JRWK=
MLMA M3vRNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnNNFJoUUN3ME2xMlk3Pjd5IN88US=> NEHPOZlUSU6JRWK=
RCM-1 M1;J[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3zTWM2OD1{LkCwN|k6KM7:TR?= M3eySnNCVkeHUh?=
MFE-280 NHPaXVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfoTmJYUUN3ME2yMlAzQDR6IN88US=> MYDTRW5ITVJ?
ES8 NIrNZ5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnTTWM2OD1{LkK1OFcyKM7:TR?= Ml34V2FPT0WU
TE-11 NFHZemNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPrTItKSzVyPUKuNlk1PzNizszN NGrRdmdUSU6JRWK=
HuO-3N1 NVrTTFNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{[0[mlEPTB;Mj60PFc5KM7:TR?= MVjTRW5ITVJ?
MHH-NB-11 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jlfGlEPTB;Mj61NVE2QCEQvF2= NEPLXYtUSU6JRWK=
TGBC11TKB MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTJwNUe2PFEh|ryP M2fq[XNCVkeHUh?=
HOP-92 M{Dld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXKTWM2OD1{LkW4O|Q{KM7:TR?= M4SzPHNCVkeHUh?=
IGR-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvKTWM2OD1{Lk[yNFM2KM7:TR?= MlvHV2FPT0WU
GOTO NEfiT|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTJwNkWzO|ch|ryP NE\Id5hUSU6JRWK=
NCI-H1650 NGGySpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWq0NYhjUUN3ME2yMlczOjF3IN88US=> NF;ROolUSU6JRWK=
NCI-H1581 NGG5R3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPwZ4tWUUN3ME2yMlc6PjhzIN88US=> NFzCZ2dUSU6JRWK=
NCI-H2405 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDmNlB7UUN3ME2yMlgzPzh{IN88US=> MV\TRW5ITVJ?
U-118-MG NVn3RpZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTJwOU[0PVEh|ryP Mmq4V2FPT0WU
DoTc2-4510 M{XTRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDmenJMUUN3ME2zMlAyPDF5IN88US=> M1HvVnNCVkeHUh?=
NCI-H596 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LVeGlEPTB;Mz6wOFk6PyEQvF2= M3TpcXNCVkeHUh?=
MPP-89 Mm\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jx[mlEPTB;Mz6wOVY3PiEQvF2= M1nMeHNCVkeHUh?=
GCIY Ml2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTNwMkC0PVEh|ryP NYXtUGNXW0GQR1XS
SW626 M2\MV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTNwMkS1OFMh|ryP M37BdHNCVkeHUh?=
OCI-AML2 M4rH[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LEbGlEPTB;Mz6zNVI4OiEQvF2= M3rSeXNCVkeHUh?=
NBsusSR NV3lfoxoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXuTWM2OD1|LkO0PVM5KM7:TR?= MnLoV2FPT0WU
AN3-CA M1[xV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTNwNESyN|gh|ryP NIHtdotUSU6JRWK=
EFM-19 M373fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\TRVIzUUN3ME2zMlQ5OzN7IN88US=> Mk[4V2FPT0WU
RVH-421 NHmxco5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTrVpA2UUN3ME2zMlU3QDd5IN88US=> M4nzcnNCVkeHUh?=
5637 NGD1SIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\HdmlEPTB;Mz62NVExOyEQvF2= M3rFcXNCVkeHUh?=
PANC-08-13 NVPneIhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjDXm1KSzVyPUOuOlM1PzJizszN NH\aT|VUSU6JRWK=
H9 M3LmVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPoPIZKSzVyPUOuOlcyPDRizszN MoTqV2FPT0WU
KARPAS-299 NVvp[IJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnYTWM2OD1|Lk[3N|YyKM7:TR?= NVzlfWNoW0GQR1XS
TE-5 NH7OfmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXSx[ZlmUUN3ME2zMlcxPzB7IN88US=> NYiyPIdqW0GQR1XS
NOS-1 NWraWXgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TjNWlEPTB;Mz63PVg{PCEQvF2= MUnTRW5ITVJ?
HH Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDsVppKSzVyPUOuPFM5PjhizszN NHvSc5RUSU6JRWK=
769-P M1H5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXrPG5KSzVyPUOuPFk2OSEQvF2= MkPNV2FPT0WU
CHP-212 NVXzcpNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mle1TWM2OD1|LkmyOVQ6KM7:TR?= NWfBbYxuW0GQR1XS
NCI-H82 NGW4NIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTNwOUW5N|Yh|ryP NV\pSnllW0GQR1XS
Mo-T NUHkW2FDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTzTWM2OD12LkC0N|EzKM7:TR?= MmPZV2FPT0WU
BB65-RCC M4\YOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFK2fYtKSzVyPUSuNFQ{QTlizszN NGXuNW9USU6JRWK=
SW1990 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrCVmdKSzVyPUSuNFU6ODhizszN NEPWTGtUSU6JRWK=
LK-2 NULWb|VFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;BfGlEPTB;ND6xNVI6OyEQvF2= M3T2TXNCVkeHUh?=
ES5 MkntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF32OopKSzVyPUSuNVM6QDVizszN MUfTRW5ITVJ?
JVM-3 NHP2U3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTRwMUiyNlIh|ryP NUnrN4pMW0GQR1XS
RPMI-7951 MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTRwMkK0NVMh|ryP Mo\OV2FPT0WU
Calu-6 M4LZTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTRwMke4PFEh|ryP MYXTRW5ITVJ?
LC-2-ad M3jscWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnHWnd{UUN3ME20MlI6PTZ6IN88US=> NGPqNJJUSU6JRWK=
SW954 M4Pacmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTRwMkm2OkDPxE1? M2CyO3NCVkeHUh?=
H-EMC-SS MmrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TGNmlEPTB;ND6zNVg{OSEQvF2= M2q3N3NCVkeHUh?=
ES3 M4T3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfzTWM2OD12LkO1OFQyKM7:TR?= NGXnbGZUSU6JRWK=
no-11 MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTRwM{W1OVQh|ryP NV7ue2x2W0GQR1XS
LAN-6 M{KzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXpTWM2OD12LkS1NVg6KM7:TR?= MnTsV2FPT0WU
FTC-133 NHzpUHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF25SnJKSzVyPUSuOVM6PSEQvF2= MmjKV2FPT0WU
8505C MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTRwNUSyN{DPxE1? MYrTRW5ITVJ?
SW620 M4rqUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjwVplJUUN3ME20MlU4ODV5IN88US=> M3HsUnNCVkeHUh?=
BCPAP NHPE[45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;TTHJKSzVyPUSuOlM1QDFizszN NVTVR|A{W0GQR1XS
SK-LU-1 NUDxdFkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXVXIZlUUN3ME20MlY3ODh7IN88US=> MmDMV2FPT0WU
NCI-H1623 NFPDSZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPEeFJKSzVyPUSuO|AzOjhizszN M4H4XnNCVkeHUh?=
C2BBe1 NFvQfHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGn4eolKSzVyPUSuO|QxODhizszN NYrZVYlXW0GQR1XS
GP5d MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLrOZNyUUN3ME20Mlc5Ozh6IN88US=> Ml22V2FPT0WU
NB6 NYCxeml3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTRwOE[yNFQh|ryP NEPzd4RUSU6JRWK=
MDA-MB-157 NUX5ZXNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTRwOEi3OkDPxE1? MlW5V2FPT0WU
UMC-11 MnX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTRwOEi5OlQh|ryP NYXtNGVIW0GQR1XS
HCC1419 M4nNUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTRwOUCwOlMh|ryP MVzTRW5ITVJ?
NCI-H2029 NFvvT2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3f5eWlEPTB;ND65OFE5PSEQvF2= M1XzdHNCVkeHUh?=
LXF-289 NFXhTmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHSWW9KSzVyPUWuNFM4OTlizszN NFrrfmJUSU6JRWK=
KINGS-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTVwMEe3OFQh|ryP NWr1TFFvW0GQR1XS
HD-MY-Z M37QO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XCeWlEPTB;NT6yN|k3QSEQvF2= M3jkZnNCVkeHUh?=
ESS-1 NVnaZW1kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvuVXM6UUN3ME21MlI2PTl5IN88US=> MofyV2FPT0WU
GI-1 NELJbHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTVwMke5NlYh|ryP MWfTRW5ITVJ?
RPMI-2650 NEDKSGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\RTWM2OD13LkO2NVYh|ryP MlfUV2FPT0WU
IA-LM NGfTeY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\Ke2tKSzVyPUWuN|k5PzFizszN MWDTRW5ITVJ?
KP-4 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDzTWM2OD13LkS2N|M1KM7:TR?= NITMd21USU6JRWK=
G-402 MknkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTVwNUG4OlUh|ryP NWf1UVd{W0GQR1XS
OS-RC-2 NEDEVoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEK4[lZKSzVyPUWuOVI3ODRizszN M4XEUnNCVkeHUh?=
NCI-H1155 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPHT5ltUUN3ME21MlU1QTV3IN88US=> M3X4bHNCVkeHUh?=
OE19 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWK3fJVZUUN3ME21MlY5PjJ2IN88US=> M{HYNXNCVkeHUh?=
U-2-OS Mo\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPxS|NWUUN3ME21Mlg6ODF|IN88US=> MVXTRW5ITVJ?
SCC-15 Mm\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4f6O2lEPTB;NT65N|Y3OiEQvF2= MXXTRW5ITVJ?
NCI-H630 NFvWNoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\Sc4FKSzVyPUWuPVk1ODRizszN MWLTRW5ITVJ?
PFSK-1 NUXEdoV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPEZ4M4UUN3ME22MlA2OjV7IN88US=> M1:yUXNCVkeHUh?=
NCI-H1770 NVmxT2pHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTIb4NmUUN3ME22MlIxQDd2IN88US=> NEj4fZBUSU6JRWK=
SK-MEL-3 NEDVO4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTZwNEK5NVUh|ryP NV\WPJJQW0GQR1XS
LB1047-RCC MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfTTWM2OD14LkS3OlI2KM7:TR?= M1u5fXNCVkeHUh?=
NCI-H446 MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfiNo5rUUN3ME22MlYzQTJ3IN88US=> MnP4V2FPT0WU
SW780 M2TVUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTZwN{CxPFUh|ryP NV2xNphYW0GQR1XS
NEC8 MlvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHTfYxKSzVyPU[uO|Y3OyEQvF2= MknqV2FPT0WU
NOMO-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHM[ZdKSzVyPU[uO|gyOTFizszN NFHPdlBUSU6JRWK=
COLO-668 NFHOUnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYGxS4hFUUN3ME22Mlg1Ozh5IN88US=> M132WHNCVkeHUh?=
MC116 M4fobWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfDTWM2OD14LkmzPFk4KM7:TR?= MmexV2FPT0WU
HCC1937 MkC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fvOGlEPTB;Nj65PVI2OSEQvF2= M1K5[HNCVkeHUh?=
NCI-N87 NGSxR3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHDZ|FKSzVyPUeuNVkzQTNizszN MX;TRW5ITVJ?
COLO-320-HSR MnS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF:5UFhKSzVyPUeuNlI4OzhizszN NFrDeFdUSU6JRWK=
HCC1806 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTdwMk[wOFQh|ryP NWL3fm51W0GQR1XS
OVCAR-3 M{O1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13VPGlEPTB;Nz6zN|A{QCEQvF2= MXvTRW5ITVJ?
NUGC-3 NG\tWodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTdwM{m2PVQh|ryP M2H0[HNCVkeHUh?=
SW1783 MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEj3fZJKSzVyPUeuOFMyPzVizszN MlnGV2FPT0WU
GCT MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPu[FJKSzVyPUeuOVY6ODZizszN NHHBd|FUSU6JRWK=
NCI-H2126 Mof1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTdwN{O2NlUh|ryP NIDVb4ZUSU6JRWK=
MEL-HO NFztTXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHlTWM2OD15Lke3NFU1KM7:TR?= MX3TRW5ITVJ?
CAPAN-1 Mm\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknpTWM2OD15Lke3N|U4KM7:TR?= NIToeVlUSU6JRWK=
SW756 M2rWUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVGwVIdMUUN3ME23Mlc5OzN|IN88US=> M1L0SnNCVkeHUh?=
SKG-IIIa MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFz1NVdKSzVyPUeuPFE5QTJizszN NILn[5NUSU6JRWK=
HCE-T MmrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUO4eXAxUUN3ME23Mlg4Pzh|IN88US=> MULTRW5ITVJ?
Ca-Ski MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jGUWlEPTB;Nz65PVM5OyEQvF2= NGixbllUSU6JRWK=
COLO-684 NE\BR3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXq2NW5NUUN3ME24MlAyQDF6IN88US=> NETNUo5USU6JRWK=
KYSE-70 M{\odGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH22[3hKSzVyPUiuNFc4OjlizszN M2\xdnNCVkeHUh?=
TI-73 M1qzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\IXG1KSzVyPUiuNlU5PTFizszN NWq5NVZZW0GQR1XS
BT-20 NFe2d5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPhRW1KSzVyPUiuNlYxPTJizszN NIWweGdUSU6JRWK=
MHH-ES-1 M17BcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjzOmJKSzVyPUiuOVE5OzRizszN M33zWnNCVkeHUh?=
TE-12 M2T5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRThwNUm5N|Eh|ryP MnjpV2FPT0WU
YH-13 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVSyfoZ2UUN3ME24MlYyODB6IN88US=> NGnDZ4NUSU6JRWK=
SF126 Mn3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M332XGlEPTB;OD64N|g3PSEQvF2= MoHOV2FPT0WU
J82 MoD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRThwOUCwN|gh|ryP NVTTe3BvW0GQR1XS
RCC10RGB NVe5bok6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fYSWlEPTB;OD65PVU3OSEQvF2= NGOxNmFUSU6JRWK=
SK-UT-1 M2e0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTlwMES5OFUh|ryP Mmq5V2FPT0WU
LB2241-RCC NEX2c3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37JTGlEPTB;OT6xPVE{PyEQvF2= MlvJV2FPT0WU
LB996-RCC M3vYU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTlwMUm4PUDPxE1? NW\SZoNvW0GQR1XS
EPLC-272H NY\aTG1{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnYNXlKSzVyPUmuN|c3PTdizszN NYf3[ZN3W0GQR1XS
CTV-1 MmTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoX5TWM2OD17LkW2OVMzKM7:TR?= MmjLV2FPT0WU
HSC-2 MlPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjaTWM2OD17LkW3OVUh|ryP NEfWdpVUSU6JRWK=
SK-MEL-28 M{jQ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXLTnBKSzVyPUmuOlE5QTNizszN MXLTRW5ITVJ?
MMAC-SF NGqzTG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVL1XGw3UUN3ME25MlY5PzVizszN MXzTRW5ITVJ?
CP50-MEL-B NVPibHFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTlwN{W3PFIh|ryP MYDTRW5ITVJ?
HT-1080 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\xVmlEPTB;OT63O|c{QSEQvF2= Mo\KV2FPT0WU
HEC-1 NXT6bYNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\hOHpKSzVyPUGwMlM{PTJizszN MnLUV2FPT0WU
AGS Mn;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4O1SGlEPTB;MUCuN|c1KM7:TR?= M1jSOHNCVkeHUh?=
GAMG MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jvWGlEPTB;MUCuOVE3OiEQvF2= MlqwV2FPT0WU
SW48 M1:5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1ruNmlEPTB;MUCuOVE5QSEQvF2= NXjJdIM{W0GQR1XS
U031 NWLBO2NXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLyTWM2OD1zMD61PVA5KM7:TR?= Mnv3V2FPT0WU
OVCAR-5 MnHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\XSlVKSzVyPUGwMlY1OjlizszN NYPzbHBxW0GQR1XS
SF295 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTFyLk[3NFQh|ryP M2fWdnNCVkeHUh?=
BHT-101 M4XaT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHCUJRKSzVyPUGwMlcyPzdizszN M1PPVXNCVkeHUh?=
VMRC-RCZ MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoraTWM2OD1zMT6zNlAyKM7:TR?= M1PSZXNCVkeHUh?=
ACHN NFfFVGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zPWmlEPTB;MUGuOFIyOSEQvF2= NVfGRoU4W0GQR1XS
NCI-H526 M4T5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTFT|ZKSzVyPUGxMlUxPDNizszN NELIWXdUSU6JRWK=
MN-60 NV73[nloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;YTWM2OD1zMT61N|kh|ryP MoPXV2FPT0WU
NCI-H2291 M2n4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrIRZFKSzVyPUGxMlU1PjZizszN NEDRc5dUSU6JRWK=
SCC-25 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HmW2lEPTB;MUGuO|U2PiEQvF2= MVnTRW5ITVJ?
SK-MEL-2 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTq[3BKSzVyPUGxMlc3OzdizszN NWO4UHVjW0GQR1XS
SN12C NWP5UoIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3H5[GlEPTB;MUGuPVM2PSEQvF2= MnXUV2FPT0WU
NCI-H69 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{G1ZmlEPTB;MUKuOFI{PCEQvF2= NXnISZFMW0GQR1XS
ME-180 Mo\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTF{LkewOVQh|ryP MlHLV2FPT0WU
MC-IXC M{DOW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1G3[mlEPTB;MUKuO|UyQCEQvF2= M{PEXHNCVkeHUh?=
NCI-H2347 NULV[IU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfzW3JLUUN3ME2xNk44PjF2IN88US=> NFr3[VlUSU6JRWK=
M059J NEexNGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTSem5wUUN3ME2xNk44PzJ5IN88US=> NGXpdnVUSU6JRWK=
A2058 NFfZTVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LNPWlEPTB;MUKuPFY5OSEQvF2= M2TaUnNCVkeHUh?=
VA-ES-BJ NF;IVFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEf1TpVKSzVyPUGyMlg4QDVizszN MnTYV2FPT0WU
Ca9-22 MmnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojETWM2OD1zMj65OFUyKM7:TR?= NGf3UFBUSU6JRWK=
KNS-42 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXpTWM2OD1zMj65PVg1KM7:TR?= MXvTRW5ITVJ?
LoVo Mk[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV35W5BjUUN3ME2xN{4zOzF|IN88US=> M33jSHNCVkeHUh?=
AM-38 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXX2eJNoUUN3ME2xN{4zPTZ4IN88US=> M{X0VHNCVkeHUh?=
NB5 MkPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7vTWM2OD1zMz6zO|UzKM7:TR?= MYDTRW5ITVJ?
L-363 NYDCZVl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rKNmlEPTB;MUOuOFA{OyEQvF2= NX3xXpdNW0GQR1XS
SK-MEL-30 M3TteWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzDeZdKSzVyPUG0MlA3PDVizszN NGTmbZdUSU6JRWK=
NCI-H1563 NFL5UZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3P3SWlEPTB;MUSuOlA{QSEQvF2= M4jW[XNCVkeHUh?=
NCI-H2228 Mn7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHkNmpGUUN3ME2xOE43ODd5IN88US=> MVTTRW5ITVJ?
MFM-223 NYHYTlRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fET2lEPTB;MUWuNVgyOyEQvF2= NG\wfVVUSU6JRWK=
LB831-BLC NWLnR2R6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TmeGlEPTB;MUWuNlc3PyEQvF2= NI\jfG5USU6JRWK=
SW872 NXXSfFI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnniTWM2OD1zNT6zNFg3KM7:TR?= MWfTRW5ITVJ?
NCI-H522 NXvaXXltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXnTWM2OD1zNT6zN|A3KM7:TR?= NVfjPFV3W0GQR1XS
EW-1 M2POOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLmTWM2OD1zNT61OFYzKM7:TR?= MlHVV2FPT0WU
HN MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFn2O|ZKSzVyPUG1MlU6PDJizszN MWnTRW5ITVJ?
SW837 MoTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV22fIo{UUN3ME2xOU44QDR5IN88US=> M2LwTHNCVkeHUh?=
SCC-9 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnHNGhMUUN3ME2xOU45OTF2IN88US=> NFLY[WlUSU6JRWK=
MKN7 NU\FfmJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPGW|lsUUN3ME2xOU46PzN{IN88US=> Mn;QV2FPT0WU
KYSE-410 MoPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY[3bnVmUUN3ME2xOk42QTFizszN MkDmV2FPT0WU
SK-N-DZ M4D3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LSU2lEPTB;MU[uOlEyPiEQvF2= NFPhPWtUSU6JRWK=
COR-L105 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTF4Lk[1Nlgh|ryP NEXKfnJUSU6JRWK=
LB2518-MEL MlnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTF4LkizPFkh|ryP NF32dmFUSU6JRWK=
OVCAR-4 M2rXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH33bVdKSzVyPUG2Mlg5PjJizszN NITkc5pUSU6JRWK=
TK10 NWfpd|N[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTF4Lkm0O|Mh|ryP NIXkS4xUSU6JRWK=
KNS-62 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2f5R2lEPTB;MU[uPVc4PyEQvF2= NGDBWZhUSU6JRWK=
RPMI-8866 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\WfGlEPTB;MUeuNVc{OiEQvF2= NWjNfmd2W0GQR1XS
HuP-T4 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoGxTWM2OD1zNz6yOFk2KM7:TR?= MYPTRW5ITVJ?
CGTH-W-1 NV30SpZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTF5LkWyNVkh|ryP M1;uT3NCVkeHUh?=
T-24 NYXTO2ZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEG3eWhKSzVyPUG3MlU{PDdizszN NVrDS4E4W0GQR1XS
HT-3 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Pne2lEPTB;MUeuOVkyPCEQvF2= M4i3XXNCVkeHUh?=
KS-1 MofjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjnV4tKSzVyPUG3MlY4OyEQvF2= MmrKV2FPT0WU
NCI-H1792 M3mxdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorZTWM2OD1zNz63PVgh|ryP NUPldJJ7W0GQR1XS
ABC-1 M{\J[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fGfmlEPTB;MUeuPFE1OSEQvF2= MXLTRW5ITVJ?
BPH-1 M3TnT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTF6LkG2PFUh|ryP NWXaSoFTW0GQR1XS
A431 NV;0RYw{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;Z[mlEPTB;MUiuOFEzPyEQvF2= NG\QfWxUSU6JRWK=
T98G M3fGSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTF6LkWxOVch|ryP MWPTRW5ITVJ?
BHY NH25ZphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTF6Lki2PUDPxE1? NIjXTGZUSU6JRWK=
Capan-2 M{X5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1OzWGlEPTB;MUiuPVA4QCEQvF2= NFfyZWpUSU6JRWK=
MDA-MB-175-VII M1TPSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnqxTWM2OD1zOD65NlA6KM7:TR?= NWfaSZptW0GQR1XS
CAL-27 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTF7LkC0PFch|ryP MWjTRW5ITVJ?
AsPC-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFP0d|NKSzVyPUG5Mlg3PTdizszN NH\5S3lUSU6JRWK=
KU812 M{L6TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYT3XZNpUUN3ME2xPU46PTd|IN88US=> NX2xeZVZW0GQR1XS
NCI-H441 MonDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTJyLkCwNUDPxE1? M1fmSnNCVkeHUh?=
Mewo M3HDdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWS4OG1IUUN3ME2yNE4yOjh6IN88US=> MXPTRW5ITVJ?
SK-MEL-24 NU\mVJo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTJyLkG0O|ch|ryP NYTOfIdpW0GQR1XS
NCI-H727 MmrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfXTWM2OD1{MD6yO|A1KM7:TR?= MnLYV2FPT0WU
EKVX NETsN4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rBZWlEPTB;MkCuOlA3KM7:TR?= NUPI[|V7W0GQR1XS
RT-112 M{e5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHy4d3dKSzVyPUKwMlYyOjJizszN MlnuV2FPT0WU
CAMA-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfIW|cxUUN3ME2yNE46QDB|IN88US=> MmD1V2FPT0WU
SW900 M4HpRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3q5bWlEPTB;MkGuNFE1QSEQvF2= MlXEV2FPT0WU
NCI-H23 NHW3[VlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4n0TGlEPTB;MkGuNVI4PyEQvF2= NXrFfpRyW0GQR1XS
SK-PN-DW NXLOO4tzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojHTWM2OD1{MT6xOlQ6KM7:TR?= NHG4cWtUSU6JRWK=
BB30-HNC MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmf3TWM2OD1{MT6yO|Q2KM7:TR?= M17lTHNCVkeHUh?=
VM-CUB-1 M3jXc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDJVIlKSzVyPUKxMlM2OzZizszN NY\VemJ7W0GQR1XS
IST-MEL1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTJzLkO2PVIh|ryP NY\xPZdxW0GQR1XS
CTB-1 MlToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M36ybGlEPTB;MkGuOFc2PSEQvF2= NVXvWIVZW0GQR1XS
LCLC-103H NXvz[WY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnjU3lyUUN3ME2yNk4yPTh{IN88US=> MWLTRW5ITVJ?
PANC-03-27 M4Tyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTJ{LkWxOlkh|ryP NFnLc5RUSU6JRWK=
HTC-C3 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\iNGlEPTB;MkKuOVU2PSEQvF2= M1XvRnNCVkeHUh?=
TE-8 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjuTWM2OD1{Mz6yOVY2KM7:TR?= M2XxTHNCVkeHUh?=
NCI-H292 M1PRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrRTWM2OD1{NT6zOVM3KM7:TR?= NE\lcIlUSU6JRWK=
COLO-680N M4\kPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTJ3Lk[zNlkh|ryP MkDBV2FPT0WU
KYSE-520 M2qwPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LqfWlEPTB;MkWuOlQ1KM7:TR?= MXPTRW5ITVJ?
NB10 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTJ4LkOxNVch|ryP NE\iS|RUSU6JRWK=
NCI-H661 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHlTWM2OD1{Nj60O|E{KM7:TR?= MUnTRW5ITVJ?
GMS-10 MmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPyTWM2OD1{Nj64OlM5KM7:TR?= MVnTRW5ITVJ?
NCI-H2122 MoPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jlUmlEPTB;Mk[uPVk6QCEQvF2= MnexV2FPT0WU
OVCAR-8 MofhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[5SWNlUUN3ME2yO{4xPjN6IN88US=> MYfTRW5ITVJ?
DJM-1 M3;SZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTJ5LkG0OVQh|ryP MVnTRW5ITVJ?
UACC-893 MlHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHvRZNKSzVyPUK3Mlk5PzhizszN NF36Z5lUSU6JRWK=
C8166 Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LKRmlEPTB;MkiuOlk{QCEQvF2= M1\1U3NCVkeHUh?=
NCI-H1693 MkXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTJ6Lk[5O|Uh|ryP Mo\NV2FPT0WU
TYK-nu M3LpfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTKOJhKSzVyPUOwMlA{PDVizszN NFH6dGRUSU6JRWK=
SW1710 M{K4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTNyLkGyOkDPxE1? MYXTRW5ITVJ?
A375 NXP6RllbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjZdndKSzVyPUOwMlMzPDNizszN NYXRcG5QW0GQR1XS
HMV-II M3HER2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1L3PGlEPTB;M{GuN|U6OiEQvF2= NH\lR3ZUSU6JRWK=
NCI-H2087 M17YeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrROIFKSzVyPUOxMlY{PTJizszN M1HTSnNCVkeHUh?=
CAL-54 NYfFdZAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTNzLkeyOFEh|ryP M4m5OXNCVkeHUh?=
HCC70 MlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Dy[WlEPTB;M{KuNVM5PyEQvF2= MWPTRW5ITVJ?
ES1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTN{LkOwOlIh|ryP NHfENGFUSU6JRWK=
NCI-H1355 MlLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XMdGlEPTB;M{OuNlA1KM7:TR?= MXLTRW5ITVJ?
CFPAC-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkW2TWM2OD1|Mz6yN|MzKM7:TR?= MnTTV2FPT0WU
MKN28 MmTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1frSmlEPTB;M{OuN|gxQSEQvF2= NITHToVUSU6JRWK=
HDLM-2 M4L4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXWTWM2OD1|Mz62PVMyKM7:TR?= MV7TRW5ITVJ?
PANC-10-05 MkXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXTTWM2OD1|ND6xNFE1KM7:TR?= MUTTRW5ITVJ?
SAS M4nzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLsfoFKSzVyPUO0MlQ2PjVizszN MmPuV2FPT0WU
HCC1395 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3izZ2lEPTB;M{SuO|E5PiEQvF2= MlLKV2FPT0WU
8305C NFzTR4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnz2TWM2OD1|NT64OFE2KM7:TR?= M3Pke3NCVkeHUh?=
KM12 M3fGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXS3ZnpxUUN3ME2zOk44PTR5IN88US=> Mnm5V2FPT0WU
SW1116 MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIC5VJhKSzVyPUO3MlU6QTJizszN NFnue2tUSU6JRWK=
SK-MEL-1 MnWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnOeWx5UUN3ME2zPE4{Ozh7IN88US=> NWXCfmt{W0GQR1XS
HCC2218 NYPVR|VUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTN6Lk[1NVkh|ryP MYrTRW5ITVJ?
T84 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFr0b4hKSzVyPUO4Mlc1ODlizszN NUj6OXFnW0GQR1XS
ETK-1 NHPIcWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TIdWlEPTB;M{muNFIzKM7:TR?= NVjVR5MyW0GQR1XS
COLO-800 M2DyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVX5N2lXUUN3ME2zPU4{QDZ6IN88US=> NUL6WI5zW0GQR1XS
CAL-12T M4\pSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LjZ2lEPTB;M{muOVI5OSEQvF2= M334[3NCVkeHUh?=
ACN MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3zTWM2OD12MD60PVEyKM7:TR?= NFLCd4xUSU6JRWK=
SJSA-1 M2fnWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXNfoRFUUN3ME20NU4yPTl4IN88US=> NIHVUnpUSU6JRWK=
PSN1 Ml61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HKT2lEPTB;NEGuNVc1QSEQvF2= Mn7iV2FPT0WU
D-566MG MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTRzLkKwPFYh|ryP M4rjeHNCVkeHUh?=
EGI-1 M1ThZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWC3NYpzUUN3ME20Nk41OjhizszN NFnKXHpUSU6JRWK=
A204 MlL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzCb|g{UUN3ME20Nk43Ozh6IN88US=> MUXTRW5ITVJ?
Saos-2 MofzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTR{LkizOlkh|ryP Mle0V2FPT0WU
SNU-C2B MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LNT2lEPTB;NEOuOlg4QCEQvF2= MnnDV2FPT0WU
HLE NXH4bmk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTR2LkC4OVYh|ryP MU\TRW5ITVJ?
SW1463 NYjY[ItRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;OdWlEPTB;NESuPVk4OSEQvF2= M1;HNHNCVkeHUh?=
DSH1 M3PFOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTR3LkCwN|Mh|ryP NULKcI1OW0GQR1XS
MCF7 NWjaPIQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;neHdKSzVyPUS1MlUxPTFizszN MkOxV2FPT0WU
K5 Mnn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\jTWM2OD12NT65OFA2KM7:TR?= M1jjN3NCVkeHUh?=
NCI-H358 M3TafGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTR5LkKxOUDPxE1? MXPTRW5ITVJ?
NCI-H2030 NUPk[3lvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rn[WlEPTB;NEeuNlM4PCEQvF2= NIH5OYxUSU6JRWK=
SW948 NYfHTo1nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PqZ2lEPTB;NEeuOFY1KM7:TR?= MWfTRW5ITVJ?
BALL-1 M2[5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M32wOGlEPTB;NEeuOlE3QCEQvF2= MWDTRW5ITVJ?
TE-9 M17JU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\FUY17UUN3ME20O{46PThzIN88US=> NGXIN2dUSU6JRWK=
SK-N-FI M3;GUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjNTWM2OD12OD6wN|U5KM7:TR?= MkXRV2FPT0WU
KALS-1 M1;jdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPVd4dKSzVyPUS4MlEzQDlizszN Mm\MV2FPT0WU
HO-1-N-1 NVq4PZlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHyTY9{UUN3ME20PE44PDR3IN88US=> M{O4SnNCVkeHUh?=
NCI-H2452 NEPWeWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPTdZhKSzVyPUS5MlEyPTJizszN M2iyfnNCVkeHUh?=
OC-314 M1zXeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTR7Lk[4N|Qh|ryP MnG1V2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
STAT3 / pSTAT3 / STAT6 / pSTAT6 / Mcl-1 / Cleaved Mcl-1 / Bcl-xl / Bim / puma / Bik / Bax / PARP / c-Myc; 

PubMed: 26811457     


(A) Western blot analysis of expressions of STAT3/p-STAT3 and STAT6/p-STAT6 as well as antiapoptotic members (Bcl-2, Bcl-xL, and Mcl-1) after 48 h of treatments in HDLM-2 cells. (B) Western blot analysis of expressions of proapoptotic proteins (Bim, Puma, Bik, Bax, and p-Bad) as well as caspase cascade molecules (PARP and c-Myc) after 48 h of treatments. β-Actin was used as an input control.

caspase3 / cleaved caspase 3; 

PubMed: 24481442     


(b) (i) N/TERT, (ii) SINCE and (iii) SINEG2 cells were either untreated (0 μM/DMSO) or treated with increasing doses of Navitoclax (ABT-263; 0.025–30 μM) and were incubated for 24 h. Next, cells were collected and whole-cell lysates were prepared and immunoblotted against anti-full-length Caspase 3 (∼35 kDa) antibody, whereas β-actin (∼42 kDa) was used as a protein-loading control. Apoptosis was assessed through detecting the cleaved bands of Caspase-3 (∼19, 17 kDa). 

26811457 24481442
Growth inhibition assay
Cell viability; 

PubMed: 25685063     


(C) Hcc827, (D) H292, and (E) H1993 cells were treated with increasing concentrations of albendazole or mebendazole in the presence of navitoclax (0, 1, 2, and 4 μM). Viability was determined after 1 day.

25685063
In vivo When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]

Protocol

Kinase Assay:

[1]

- Collapse

Affinity determination:

Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research:

[1]

- Collapse
  • Cell lines: SCLC cell lines
  • Concentrations: 0-1 μM
  • Incubation Time: 48 hours
  • Method:

    Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice
  • Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
  • Dosages: 100 mg/kg/d
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (102.6 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+corn oil
For best results, use promptly after mixing.
7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 974.61
Formula

C47H55ClF3N5O6S3

CAS No. 923564-51-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03181126 Recruiting Drug: Navitoclax|Drug: Chemotherapy|Drug: Venetoclax Acute Lymphoblastic Leukemia (ALL)|Lymphoblastic Lymphoma AbbVie November 27 2017 Phase 1
NCT02520778 Recruiting Drug: Navitoclax|Drug: Osimertinib Advanced Lung Non-Squamous Non-Small Cell Carcinoma|EGFR Exon 19 Deletion Mutation|EGFR NP_005219.2:p.L858R|EGFR NP_005219.2:p.T790M|Metastatic Lung Non-Squamous Non-Small Cell Carcinoma|Stage III Lung Non-Small Cell Cancer AJCC v7|Stage IIIA Lung Non-Small Cell Cancer AJCC v7|Stage IIIB Lung Non-Small Cell Cancer AJCC v7|Stage IV Lung Non-Small Cell Cancer AJCC v7 National Cancer Institute (NCI) March 31 2016 Phase 1
NCT02591095 Completed Drug: ABT-263 Platinum-resistant or Refractory Ovarian Cancer Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Cancer Research Hospital Program January 2016 Phase 2
NCT02079740 Recruiting Biological: Navitoclax|Drug: Trametinib Advanced Malignant Solid Neoplasm|Malignant Female Reproductive System Neoplasm|Metastatic Malignant Solid Neoplasm|Recurrent Lung Carcinoma|Recurrent Malignant Solid Neoplasm|Recurrent Pancreatic Carcinoma|Stage III Lung Cancer AJCC v7|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IV Lung Cancer AJCC v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Unresectable Malignant Solid Neoplasm National Cancer Institute (NCI) March 7 2014 Phase 1|Phase 2
NCT00887757 Completed Drug: ABT-263|Drug: gemcitabine Solid Tumors AbbVie|Genentech Inc. September 2009 Phase 1
NCT00888108 Completed Drug: ABT-263|Drug: Docetaxel Solid Tumor Abbott|Genentech Inc. July 2009 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?

  • Answer:

    S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.

  • Question 2:

    Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?

  • Answer:

    According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy Navitoclax (ABT-263) | Navitoclax (ABT-263) supplier | purchase Navitoclax (ABT-263) | Navitoclax (ABT-263) cost | Navitoclax (ABT-263) manufacturer | order Navitoclax (ABT-263) | Navitoclax (ABT-263) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID